Germany: Data quality proves Bayer's Eylea blind spot in battle against Novartis' Lucentis
This article was originally published in Scrip
Executive Summary
These is no evidence that Bayer/Regeneron's Eylea (aflibercept) offers any benefits over Novartis' Lucentis for treating wet AMD, according to IQWiG, the body the conducts the preliminary scientific assessment for Germany's AMNOG health technology appraisals.